药物递送载体靶向治疗中枢神经系统淋巴瘤的研究进展

中枢神经系统淋巴瘤(central nervous system lymphoma,CNSL)少见且治疗困难.目前主流方案多为采用大剂量可通过血脑屏障(blood brain barrier,BBB)的化疗药物静脉给药或治疗有效的药物鞘内注射给药治疗,然而效果欠佳.许多外周疗效佳的化疗药物难以跨越BBB,或进入中枢神经...     

超声联合微泡介导血脑屏障开放及其在中枢神经系统疾病治疗中的作用

血脑屏障(blood-brain barrier,BBB)是一种介于外周循环系统与中枢神经系统之间的动态结构,起着守门员的作用,在维持机体内环境稳定的同时也阻碍了大多数治疗性药物进入大脑.聚焦超声联合微泡以非侵入的方式瞬时、局部可逆开放BBB,有利于药物分子的跨脑转运和中枢神经系统疾病的多功能诊疗.该文详细介绍了血脑屏...     

脑靶向寡核苷酸药物策略用于衰老相关脑部疾病治疗

寡核苷酸药物近10年发展迅速,已有多款应用于临床治疗。因其设计便捷、序列灵活、特异性高,有望解决许多靶点难成药的困境,并且其临床转化周期和成本较低,目前已成为新兴生物技术药物研发的前沿领域。脑部疾病包括多种目前无法治愈的疾病,如神经退行性疾病、胶质瘤、运动神经元疾病等,其中很多与年龄相关,被认为是衰老相关脑部疾病。因其病因复杂,许多靶点难成以药,同时由于脑部特殊屏障系统“血脑屏障”的存在,导致大部分药物无法实现脑部病灶的有效积累,众多小分子药物遭遇临床转化失败。寡核苷酸类药物的特异性和序列灵活性提供了新的成药可能性,但同样面临脑部递送的挑战。尽管目前已有多款寡核苷酸类药物应用于医疗市场,但脑靶向寡核苷酸药物仍然极为罕见,随着纳米递送和脑靶向基团研究的逐渐成熟,未来5~10年寡核苷酸药物用于脑部疾病治疗将成为可能。本文针对本领域重点话题如寡核苷酸药物临床批准的应用案例、脑靶向寡核苷酸药物的递送瓶颈和当前策略,以及衰老相关脑部疾病的寡核苷酸药物潜在靶点进行了梳理,同时对临床转化中的难点和面临的挑战展开了综述和讨论。     

跨越血脑屏障

由于血脑屏障的存在,许多神经中枢系统疾病的潜在治疗药物在应用中受到限制,故在寻找治疗该类疾病的新方法和新药物时,人们必须考虑如何有效地使药物穿越血脑屏障进入脑细胞以达到治疗的目的,从最初人为地开放血脑屏障,到现在利用分子生物学的方法寻找和构建合适的载体携带药物进入脑细胞,本文综述了目前已经建立的和正在探索中的几种方法。     

胰岛素对中枢神经系统疾病的影响

越来越多的实验证据和临床资料表明,胰岛素在中枢神经系统中发挥重要作用。多种动物脑内有高水平的胰岛素,而且神经元和胶质细胞上均存在胰岛素受体和胰岛素第二信使系统。很多神经性疾病的发病机制都和胰岛素水平或胰岛素敏感性有关。同样,胰岛素样生长因子对神经元功能也有一定的调节作用。胰岛素和包括胰岛素样生长因子在内的多种神经营养因子,在治疗神经退行性疾病方面被人类寄予了厚望。     

非侵入性基因治疗在中枢神经系统疾病中的应用

非侵入性地将具有治疗作用的基因通过血脑屏障输送至脑内,以治疗中枢神经系统疾病,是生物学领域研究的难点和热点,而应用适宜的转运载体是解决这一难题的有效途径。使用病毒载体或非病毒载体,已成功进行非侵入性基因治疗的中枢神经系统疾病有实验性运动神经疾病、脑部肿瘤和帕金森病等。随着对脑微血管内皮细胞上的受体的研究和新型载体的开发,应用非侵入性基因治疗中枢神经系统疾病将会更为广泛。     

重组抗体药物研究进展及应用

重组抗体药物的发展经历了鼠源单克隆抗体（McAb）、人 鼠嵌合抗体、人源化抗体和全人抗体等阶段,目前初步应用于抗肿瘤、抗自身免疫病、抗感染等领域。保持和提高抗体的亲和力、降低抗体的免疫原性是抗体药物基因工程改造的两大原则。在嵌合抗体成功的基础上,通过CDR移植、表面修饰、抗体库以及转基因鼠技术,逐步提高人源化程度至100%。然而,实验室水平的研究结果与实际应用仍然存在一定差距。就重组抗体药物的基本概况、现存的问题与可能的解决办法以及在肿瘤、病毒性疾病和阿尔茨海默病治疗上的应用情况等进行了综述。     

血脑屏障与脑药物转运

血脑屏障的存在使大分子药物难以进入脑中发挥疗效。成为中枢神经系统疾病治疗的瓶颈。本就血脑屏障的结构特点、大分子药物转运入脑的途径及药物与载体间的连接策略等问题进行了综述。     

抗体库技术在抗体药物研发中的应用

单克隆抗体历经近40年曲折迂回的发展过程,完成了从实验室的研究工具到临床上不可或缺的治疗药物的角色转变,逐渐成为生物制药的明星产品。     

外泌体载体治疗在中枢神经系统疾病中的研究进展

中枢神经系统疾病包括脑血管疾病、神经退行性疾病和脑肿瘤等.血脑屏障(blood-brain barrier,BBB)阻碍了大多数通过血液循环系统输送到大脑来治疗和预防中枢神经系统疾病的药物.外泌体在细胞间物质运输和信号交流中发挥重要作用,由于其具有较小的体积、高递送效率、低免疫原性和良好的生物相容性等特点,可以通过正常...     

线粒体融合与分裂在中枢神经系统疾病中的研究进展

线粒体是一种高度动态的细胞器,通过不断的融合和分裂维持其动态平衡,参与生理病理功能调节。线粒体融合与分裂主要由融合分裂相关蛋白调控,如Drp1、Fis1、Mfn1、Mfn2、OPA1等,多种诱导因子通过调节线粒体融合分裂相关蛋白表达及活化进而调节线粒体形态和生理功能。现有研究表明线粒体融合分裂的异常可能是许多中枢神经系统疾病的发病机制之一。本文从线粒体融合分裂的分子调控机制及其在缺血性脑中风、帕金森综合征和阿尔兹海默症等中枢神经系统疾病中的研究进展方面进行综述,为相关疾病的防治提供一定参考和线索。     

单克隆抗体在畜禽病毒性传染病研究中的应用

着重阐述了单克隆抗体在畜禽病毒性传染病研究中的应用现状,单克隆抗体在病毒抗原结构与抗原表位研究、以及在畜禽病毒性传染病诊断和抗病毒治疗方面的应用,对当前单克隆抗体研究所面临的一些问题和研究方向做了分析。     

Caspase与神经系统疾病

近年来,细胞凋亡发生机制的研究已取得众多进展。研究表明,许多神经系统疾病与caspase家族有着密切联系。现将细胞凋亡的最新研究结果及其与神经系统疾病的关系,尤其是caspase家族在神经系统疾病中的主导地位作简单综述,希望由此了解神经元细胞凋亡的内在机制并达到治疗目的。     

Heterogeneity of Rat Neurofilament Polypeptides Revealed by a Monoclonal Antibody

A monoclonal antibody obtained from mice immunized with a crude neurofilament preparation from newborn rat brain revealed the existence of heterogeneity of the 200,000- and 150,000-dalton neurofilament polypeptides. On immunoblot the monoclonal antibody iC8 reacted with both the 200,000- and 150,000-dalton components in the CNS, but only with the 150,000-dalton polypeptide in sciatic nerve preparations. In addition, the 150,000-dalton polypeptide appeared as a single band in the sciatic nerve, whereas in the CNS a doublet was labeled by iC8. In contrast a second monoclonal antibody (3H5) reacted with the 200,000-dalton peptide and a single 150,000-dalton component in both the central and peripheral nervous system preparations. The differences revealed by iC8 were probably not due to phosphorylation, as the pattern of antibody binding in immunoblots was not changed by pretreatment with alkaline phosphatase. The findings suggest that different isoforms of neurofilament polypeptides are present in the nervous system.     

血脑屏障与脑血管疾病的相关研究

血脑屏障（blood brain barrier,BBB）的主要结构包括：脑毛细血管内皮细胞及其间的紧密连接（tight junction,TJ）、基底膜、基 底膜下星型胶质细胞终足。血脑屏障是存在于血液和脑组织之间的一层屏障系统,在许多大脑疾患的病理过程中,BBB 的破坏导 致通透性增高都是不可避免的一个环节。BBB是保证中枢神经系统的正常生理功能的重要屏障系统。目前已有大量关于血脑屏 障通透性在脑血管疾病中的变化研究。本文分别从血脑屏障的结构和功能,药物通过血脑屏障的方法和功能,脑缺血损伤、阿尔 茨海默病、帕金森病和多发性硬化症等不同的脑病变与血脑屏障通透性的变化及中医药应用等方面做一综述。有针对性地对 BBB和大脑疾病进行进一步的研究与探索,将会为临床治疗相关疾病带来新的视角与机遇。     

Determinants of Passive Drug Entry into the Central Nervous System

1. The blood–brain barriers restrict the passive diffusion of many drugs into the brain and constitute a significant obstacle in the pharmacological treatment of central nervous system diseases and disorders. The degree of restriction they impose is variable, with some lipid-insoluble drugs effectively excluded from the brain, while many lipid-soluble drugs do not appear to be subject to any restriction.2. The ease with which any particular drug diffuses across the blood–brain barrier is determined largely by the number and strength of intermolecular forces holding it to surrounding water molecules. By quantifying the molecular features that contribute to these forces, it is possible to predict the in vivo blood–brain barrier permeability of a drug from its molecular structure. Dipolarity, polarizability, and hydrogen bonding ability are factors that appear to reduce permeability, whereas molecular volume (size) and molar refraction are associated with increased permeability.3. Increasing the passive entry of restricted drugs into the central nervous system can be achieved by disrupting the blood–brain barrier (increased paracellular diffusion) or by modifying the structure of restricted drugs to temporarily or permanently increase their lipid solubility (increased transcellular permeability).4. Competitive inhibition of outwardly directed active efflux mechanisms (P-glycoprotein and MRP, the multidrug resistance-related protein) can also significantly increase the accumulation of certain drugs within the central nervous system.     

A Novel Subtype of Prostacyclin Receptor in the Central Nervous System

Recently, in the course of our search for the prostacyclin receptor in the brain, we found a novel subtype, designated as IP2, which was finely discriminated by use of the specific ligand (15R)-16-m-tolyl-17,18,19,20-tetranorisocarbacyclin (15R-TIC) and specifically localized in the rostral part of the brain. In the present study, the tritiated compound 15R-[15-(3)H]TIC was synthesized and utilized for more specific research on IP2. The specificity of binding to rat brain regions was confirmed by use of several prostacyclin derivatives including 15S-TIC. Mapping of 15R- and 15S-[3H]TIC binding in adjacent pairs of frozen sections of rat brain demonstrated a quite similar pattern of distribution in almost all rostral brain regions, indicating that the regions may contain only the IP2 subtype. On the other hand, 15R-[3H]TIC binding was very faint as compared with 15S-[3H]TIC binding in the caudal medullary region. High densities of 15R-[3H]TIC binding sites were shown in the dorsal part of the lateral septal nucleus, thalamic nuclei, limbic structures, and some of the cortical regions. Scatchard plot analysis showed two components of high-affinity 15R-[3H]TIC binding in the rostral regions, one with a K(D) value at approximately 1 nM and the other with approximately 30 nM. These results strengthen our previous finding that a different subtype of prostacyclin receptor is expressed in the CNS, and the map with 15R-[3H]TIC obtained here could guide further studies on the molecular and functional properties of the IP2.     

Analysis of α-Bungarotoxin Binding in the Goldfish Central Nervous System

Abstract: We report here the equilibrium, kinetic, and pharmacological analysis of α-¹²⁵I-bungarotoxin (α-¹²⁵I-Bgt) binding to a Triton x-100-solubilized goldfish brain synaptosomal fraction. In addition, a refined analysis of equilibrium binding to a particulate synaptosomal fraction is presented. Equilibrium binding from both particulate and soluble fractions revealed an apparent heterogeneity of binding sites. Kinetic analysis of the soluble receptor revealed linear association kinetics and nonlinear dissociation kinetics. The dissociation curve suggested the presence of at least two rate constants. Potential sources of the binding heterogeneity found in both the equilibrium binding and dissociation kinetics experiments are (1) multiple receptor species, (2) multiple ligand species, and (3) different, possibly interconvertible, states of a single receptor type. No evidence for the first two alternatives was found. Support for the third alternative was obtained by observing the effect of cholinergic ligands on α-¹²⁵I-Bgt dissociation. Carbamylcholine and d -tubocurarine increased the apparent proportion of rapidly dissociating sites, suggesting that the two binding affinities can be interconverted and may arise from a single receptor type. Evidence concerning the identity of the α -Bgt binding protein as a nicotinic acetylcholine receptor is discussed.     

Deoxycytidine Transport and Metabolism in the Central Nervous System

Abstract: The mechanisms by which deoxycytidine enters and leaves brain, choroid plexus, and CSF were investigated by injecting [³H]deoxycytidine intraarterially, intravenously, and intraventricularly. After intracarotid injection of deoxycytidine (1.0 μM) into rats, deoxycytidine did not pass through the blood-brain barrier at a faster rate than sucrose. [³H]Deoxycytidine, either alone or together with unlabeled deoxycytidine, was infused at a constant rate into conscious adult rabbits. At 130 min, [³H]deoxycytidine readily entered CSF, choroid plexus, and brain. In brain, approx. 60% of the nonvolatile radioactivity was attributable to [³H]deoxycytidine phosphates. The addition of 0.22 mmol/kg unlabeled deoxycytidine to the infusion syringe decreased the phosphorylation of [³H]deoxycytidine in brain by approx. 50%; the addition of 2.2 mmol/kg of unlabeled deoxycytidine to the infusion syringe decreased the relative entry of [³H]deoxycytidine into CSF and brain by approx. 50 and 75%, respectively. Two hours after the intraventricular injection of [³H]deoxycytidine, [³H]deoxycytidine was rapidly cleared from CSF, in part, to brain, where approx. 65% of the [³H]deoxycytidine was converted to [³H]deoxycytidine phosphates. The intraventricular injection of unlabeled deoxycytidine with the [³H]deoxycytidine decreased the phosphorylation of [³H]deoxycytidine in the brain significantly and also decreased the clearance of [³H]deoxycytidine from the CSF. These results were interpreted as showing that the entry of deoxycytidine from blood into CSF occurs by a saturable transport system within the choroid plexus. Once within the CSF, the deoxycytidine can enter brain, undergo phosphorylation to deoxycytidine phosphates, and subsequently be incorporated into DNA.